NASDAQ:DNTH Dianthus Therapeutics (DNTH) Stock Price, News & Analysis $77.58 -3.99 (-4.89%) Closing price 04:00 PM EasternExtended Trading$77.63 +0.05 (+0.06%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Dianthus Therapeutics Stock (NASDAQ:DNTH) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Dianthus Therapeutics alerts:Sign Up Key Stats Today's Range$77.25▼$81.4650-Day Range$77.58▼$115.9652-Week Range$32.22▼$117.88Volume1.32 million shsAverage Volume966,048 shsMarket Capitalization$4.25 billionP/E RatioN/ADividend YieldN/APrice Target$129.83Consensus RatingModerate Buy Company Overview Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted antibody therapies for autoimmune diseases. The company’s approach centers on selectively modulating the complement system, an immune pathway involved in inflammation and tissue damage, with the goal of creating treatments that may offer potent disease control and convenient dosing. Dianthus’ lead investigational product is DNTH103, a fully human monoclonal antibody designed to selectively inhibit activated C1s, a key protein in the classical complement pathway. DNTH103 is engineered for extended activity and subcutaneous administration and is being evaluated in immune-mediated neuromuscular and neurological disorders, including generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy. The company is also advancing additional complement-targeted programs for autoimmune diseases. Dianthus serves global markets through its clinical development activities and is headquartered in the United States. As a development-stage biotechnology company, its products remain investigational and are subject to clinical testing and regulatory review before they may become commercially available.AI Generated. May Contain Errors. Read More Dianthus Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks53rd Percentile Overall ScoreDNTH MarketRank™: 2.633245382585 of 5 starsDianthus Therapeutics scored higher than 53% of companies evaluated by MarketBeat, and ranked 459th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingModerate Buy Consensus RatingDianthus Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialDianthus Therapeutics has a consensus price target of $129.83, representing about 67.4% upside from its current price of $77.58.Amount of Analyst CoverageDianthus Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Dianthus Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Dianthus Therapeutics are expected to decrease in the coming year, from ($3.81) to ($4.74) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dianthus Therapeutics is -18.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dianthus Therapeutics is -18.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDianthus Therapeutics has a P/B Ratio of 6.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Dianthus Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted17.20% of the float of Dianthus Therapeutics has been sold short.Short Interest Ratio / Days to CoverDianthus Therapeutics has a short interest ratio ("days to cover") of 8.32.Change versus previous monthShort interest in Dianthus Therapeutics has recently increased by 3.52%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldDianthus Therapeutics does not currently pay a dividend.Dividend GrowthDianthus Therapeutics does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.64 News SentimentDianthus Therapeutics has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Dianthus Therapeutics this week, compared to 5 articles on an average week.Search Interest2 people have searched for DNTH on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Dianthus Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Dianthus Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $26,118,913.00 in company stock.Percentage Held by Insiders3.02% of the stock of Dianthus Therapeutics is held by insiders.Percentage Held by Institutions47.53% of the stock of Dianthus Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Dianthus Therapeutics' insider trading history. Receive DNTH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Dianthus Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. DNTH Stock News HeadlinesDianthus Therapeutics Recognized Among Fortune’s 2026 Best Workplaces In BioPharmaOctober 13 at 1:28 PM | markets.businessinsider.comDianthus Therapeutics Named to Fortune’s 2026 Best Workplaces in BioPharma List Amid Company ExpansionOctober 13 at 1:28 PM | finance.yahoo.comTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 13 at 1:00 AM | Banyan Hill Publishing (Ad)Dianthus Therapeutics Recognized Among Fortune's 2026 Best Workplaces In BioPharmaOctober 13 at 8:45 AM | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Dianthus Therapeutics (DNTH)October 12 at 7:53 PM | theglobeandmail.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Rated "Moderate Buy" by Wall Street BrokeragesOctober 8, 2026 | americanbankingnews.comDianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 1, 2026 | globenewswire.comDianthus Therapeutics (NASDAQ:DNTH) CAO Edward Carr Sells 20,000 SharesSeptember 19, 2026 | insidertrades.comSee More Headlines DNTH Stock Analysis - Frequently Asked Questions How have DNTH shares performed this year? Dianthus Therapeutics' stock was trading at $41.21 on January 1st, 2026. Since then, DNTH shares have increased by 88.3% and is now trading at $77.58. How were Dianthus Therapeutics' earnings last quarter? Dianthus Therapeutics, Inc. (NASDAQ:DNTH) announced its quarterly earnings data on Tuesday, August, 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by $0.05. The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative trailing twelve-month return on equity of 22.53%. When did Dianthus Therapeutics IPO? Dianthus Therapeutics (DNTH) raised $100 million in an initial public offering on Thursday, June 21st 2018. The company issued 6,666,667 shares at $14.00-$16.00 per share. Who are Dianthus Therapeutics' major shareholders? Dianthus Therapeutics' top institutional shareholders include Sax Wealth Advisors LLC and GAMMA Investing LLC. Insiders that own company stock include Marino Garcia, Ryan Savitz, Edward Carr, Simrat Randhawa, Adam M Veness, Simon Read and Anne Mcgeorge. View institutional ownership trends. How do I buy shares of Dianthus Therapeutics? Shares of DNTH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Dianthus Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Dianthus Therapeutics investors own include Definium Therapeutics (DFTX), NVIDIA (NVDA), Palantir Technologies (PLTR), Broadcom (AVGO), Micron Technology (MU), Solid Biosciences (SLDB) and Symbotic (SYM). Company Calendar Last Earnings8/04/2026Today10/13/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (14m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 DNTH's financial health is in the Green zone, according to TradeSmith. DNTH has been in this zone for over 14 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:DNTH CIK1690585 Webdianthustx.com Phone(929) 999-4055FaxN/AEmployees92Year FoundedN/APrice Target and Rating Average Price Target for Dianthus Therapeutics$129.83 High Price Target$158.00 Low Price Target$98.00 Potential Upside/Downside+67.4%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($4.15) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$162.34 million Net Margins-10,096.95% Pretax Margin-10,096.95% Return on Equity-22.53% Return on Assets-21.55% Debt Debt-to-Equity RatioN/A Current Ratio26.10 Quick Ratio26.10 Sales & Book Value Annual Sales$2.04 million Price / Sales2,084.01 Cash FlowN/A Price / Cash FlowN/A Book Value$11.41 per share Price / Book6.80Miscellaneous Outstanding Shares54,800,000Free Float53,143,000Market Cap$4.25 billion OptionableOptionable Beta1.35 Social Links 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:DNTH) was last updated on 10/13/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Dianthus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Dianthus Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
